person · Reporting owner
Keyoung Hansoo Michael
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CalciMedica, Inc.GRAY · Entity 7804 | Director | September 29, 2020 | September 29, 2020 |
| Kairos Pharma, LTD.KAPA · Entity 8244 | Director | September 16, 2025 | November 26, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CalciMedica, Inc.
Report date September 29, 2020 · Filed September 29, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,133,596 |
Reported balance
After 2020-09-29 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-29 · Conversion · Acquired 1,133,596 · Balance 1,133,596 F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F2: These securities are held of record by AffaMed Project Limited ("AffaMed"). Mengjiao Jiang and the Reporting Person are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The Reporting Person disclaims beneficial ownership of the securities held by AffaMed except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-09-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-29 · Conversion · Disposed 1,133,596 · Balance 0 F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F2: These securities are held of record by AffaMed Project Limited ("AffaMed"). Mengjiao Jiang and the Reporting Person are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The Reporting Person disclaims beneficial ownership of the securities held by AffaMed except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date.
F2: These securities are held of record by AffaMed Project Limited ("AffaMed"). Mengjiao Jiang and the Reporting Person are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The Reporting Person disclaims beneficial ownership of the securities held by AffaMed except to the extent of his pecuniary interest therein, if any.
Kairos Pharma, LTD.
Report date September 16, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCKSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2025-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-09-16 · Grant · Acquired 10,000 · Balance 10,000 F1: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO. F2: Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. |
| COMMON STOCKSEC Table I · non-derivative | Direct | 29,084 |
Reported balance
After 2025-10-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-10-08 · Grant · Acquired 19,084 · Balance 29,084 F3: Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4: Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO.
F2: Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.
F3: Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F4: Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Nov 26, 2025 17:27 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025205 · ownership.xml · nonDerivative · entry 2 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,084 F3 · shares: Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4 · balance_after: Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting. Read SEC document |
| September 16, 2025 Filed Nov 26, 2025 17:27 UTC | Kairos Pharma, LTD. KAPA · Entity 8244 | GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025205 · ownership.xml · nonDerivative · entry 1 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO. F2 · balance_after: Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:40 UTC | CalciMedica, Inc. GRAY · Entity 7804 | ConversionSeries C Preferred Stock · Derivative | 1,133,596 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052340 · doc4.xml · derivative · entry 2 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,133,596 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F1 · price: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F2 · ownership.nature: These securities are held of record by AffaMed Project Limited ("AffaMed"). Mengjiao Jiang and the Reporting Person are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The Reporting Person disclaims beneficial ownership of the securities held by AffaMed except to the extent of his pecuniary interest therein, if any. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 20:40 UTC | CalciMedica, Inc. GRAY · Entity 7804 | ConversionCommon Stock | 1,133,596 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052340 · doc4.xml · nonDerivative · entry 1 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,133,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series C Preferred Stock automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration and has no expiration date. F2 · ownership.nature: These securities are held of record by AffaMed Project Limited ("AffaMed"). Mengjiao Jiang and the Reporting Person are the directors of AffaMed and each of them may be deemed to hold shared voting and dispositive power with respect to the shares held by AffaMed. The Reporting Person disclaims beneficial ownership of the securities held by AffaMed except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.